Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8.

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW.

Source

Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA.

Abstract

We observed a previously uncharacterized mutation in the protease substrate cleft, L23I, in 31 of 4,303 persons undergoing human immunodeficiency virus type 1 genotypic resistance testing. In combination with V82I, L23I was associated with a sevenfold reduction in nelfinavir susceptibility and a decrease in replication capacity. In combination with other drug resistance mutations, L23I was associated with multidrug resistance and a compensatory increase in replication capacity.

PMID:: 15561868; [PubMed - indexed for MEDLINE]
PMCID:: PMC529213

Free PMC Article

Images from this publication.See all images (1) Free text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

Research Support, U.S. Gov't, P.H.S.

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. [J Med Virol. 2007]
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Nájera R, Pumarola T, Alonso-Socas Mdel M, García-Bujalance S, Menéndez-Arias L, Spanish Group for the Study of Antiretroviral Drug Resistance. J Med Virol. 2007 Nov; 79(11):1617-28.
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. [Antimicrob Agents Chemother. 2...]
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PF. Antimicrob Agents Chemother. 2000 Sep; 44(9):2319-26.
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. [J Virol. 2003]
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.
Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. J Virol. 2003 Apr; 77(8):4836-47.
Review Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. [Pharmacol Ther. 2000]
Review Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.
Swanstrom R, Erona J. Pharmacol Ther. 2000 May; 86(2):145-70.
Review Novel drug resistance mutations in HIV: recognition and clinical relevance. [AIDS Rev. 2006]
Review Novel drug resistance mutations in HIV: recognition and clinical relevance.
Perno CF, Svicher V, Ceccherini-Silberstein F. AIDS Rev. 2006 Oct-Dec; 8(4):179-90.

See reviews... See all...

Cited by 4 PubMed Central articles

Molecular Basis for Drug Resistance in HIV-1 Protease. [Viruses. 2010]
Molecular Basis for Drug Resistance in HIV-1 Protease.
Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MN, Nalivaika EA, Ozen A, et al. Viruses. 2010 Nov; 2(11):2509-2535. Epub 2010 Nov 12.
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. [Curr Opin HIV AIDS. 2008]
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors.
Nalam MN, Schiffer CA. Curr Opin HIV AIDS. 2008 Nov; 3(6):642-6.
Review HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. [AIDS Rev. 2008]
Review HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
Shafer RW, Schapiro JM. AIDS Rev. 2008 Apr-Jun; 10(2):67-84.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Association of a novel human immunodeficiency virus type 1 protease substrate cl...
Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.
Antimicrob Agents Chemother. 2004 Dec ;48(12):4864-8.

PubMed
Human natural anti-Gal IgG regulates alternative complement pathway activation o...
Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces.
J Clin Invest. 1992 Apr ;89(4):1223-35.

PubMed
Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmatio...
Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim.
Antimicrob Agents Chemother. 2004 Dec ;48(12):4643-9.

PubMed
Constitutive and modulated expression of the human alpha 1 antitrypsin gene. Dif...
Constitutive and modulated expression of the human alpha 1 antitrypsin gene. Different transcriptional initiation sites used in three different cell types.
J Clin Invest. 1992 Apr ;89(4):1214-22.

PubMed
Use of a computerized guideline for glucose regulation in the intensive care uni...
Use of a computerized guideline for glucose regulation in the intensive care unit improved both guideline adherence and glucose regulation.
J Am Med Inform Assoc. 2005 Mar-Apr ;12(2):172-80. Epub 2004 Nov 23 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 4 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information